BCL2 and acute myeloid leukemia: For this purpose, we evaluated the ex vivo efficacy of AZD-5991 on the same primary AML cohort (27 out of 32 total samples), comparing the determined AUC values with the BCL2-family metrics outlined in Fig. 4 (Supplementary Data Set 2).